NV-KALRAY
21.5.2024 14:07:34 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a technology innovator building software and hardware solutions that accelerate data-intensive workflows, announced Ngenea® for AI, a new edition of its Kalray Data Acceleration Platform specifically fine-tuned for AI data pipelines. As AI demands new ways to ingest and access massive volumes of data, Ngenea for AI helps teams speed up performance, simplify data management and open their data assets to new AI-powered use cases.
Ngenea for AI is the companion to two Ngenea editions for Media & Entertainment and HPC customers, respectively. The new Ngenea for AI empowers AI innovators to speed up their ingest performance and access their unstructured data from a unified, global name space. Kalray debuted Ngenea for AI at Dell Technologies World 2024 in Las Vegas today, where the software’s performance on Dell servers is being showcased in the Kalray Booth #1026.
The generative AI (GenAI) market is predicted to see 42% compound annual growth rate (CAGR) across the next 10 years into a $1.3 trillion space, from just $40 billion in 2022 (Bloomberg Intelligence). Yet innovative AI constructs such as large language models (LLMs) and Retrieval-Augmented Generation (RAG), and applications including Smart Vision and GenAI, are challenging the ability of IT systems to move data to and from their massive data stores.
ENABLING GENAI AND RAG
Ngenea for AI adds data indexing and search capabilities, which users can leverage to feed any data to Smart Vision, GenAI and RAG applications effortlessly. The new offering enables AI customers to fully harness their existing assets when deploying GenAI applications, regardless of where the data is stored. These GenAI and RAG capabilities simplify and automate what would otherwise be a complex workflow from a data management aspect.
”Fast AI processing is mission-critical to our business of detecting railcar anomalies before they lead to breakdowns or derailments. With Ngenea deployed along with Dell Technologies products, Duos achieved a 120x performance boost on our Railcar Inspection Portal (RIP®) solution, and an 8x increase in inspection accuracy. Working with Kalray helped us put railroads at the forefront of innovation,” said Jeff Necciai, chief technology officer of Duos Technologies.
HIGH-PERFORMANCE STORAGE TIER TO FEED GPUS EFFORTLESSLY
The Ngenea for AI platform also incorporates a high-performance storage tier for the most data-intensive AI workloads. The tier is powered by a proven high-performance parallel file system that can easily manage petabytes of data and billions of files – whether data live on the edge, in the cloud, or on premises. This allows customers and partners to maximize the value of their GPU investment, without rip-and-replace deployments.
With Ngenea, AI innovators:
- Accelerate AI workflows by optimizing AI data pipelines and enhancing the overall speed and efficiency of AI operations.
- Boost the AI model performance by feeding data to GPUs faster, allowing for quicker computations and accelerated insights.
- Gain advanced data indexing capabilities that enable Generative AI and RAG applications to deliver more refined search functionalities, enabling more effective queries and a more strategic utilization of AI models.
- Facilitate a controlled and optimized connection between company data and a suite of third-party AI-powered tools, ensuring seamless integration and data synergy.
Optional hardware acceleration via Kalray’s DPUs including the TURBOCARD4 (TC4) allows parallel processing in an asynchronous way for ultra-demanding workflows, via a complementary architecture to GPUs.
“Even with the tremendous commitment that C-suite leaders are making to AI, very few CIOs have the sizable budgets required to deploy a new system solely for an AI rollout,” said Scott Sinclair, practice director, infrastructure, and modernization, at the Enterprise Strategy Group TM. “Innovative use cases that enable enterprises to leverage their existing infrastructure and still deploy novel AI applications address a sizable untapped need in the market.”
AI TOOLKIT FOR EASY INTEGRATION
Ngenea for AI includes an AI Toolkit that Kalray partners can use for easy integration of their applications with Ngenea. For example, when integrating Ngenea with Perifery Vision AI, users can intuitively search for historical content across a vast amount of data on locations, types, and collections.
“Traditional data centers weren’t built for massive data sets found in AI workloads – or to process these workloads rapidly and efficiently,“ said Eric Baissus, CEO of Kalray. “Kalray’s Ngenea for AI is the data acceleration platform for the AI age – software that elevates performance on existing servers and storage and provides toolkits that streamline application integration. With our software, enterprises and service providers can feed GPUs effortlessly - optimizing data movement and orchestration as the foundation of their infrastructure - so that AI genuinely delivers a competitive edge.“
The Ngenea for AI platform joins two other Ngenea editions that streamline application integration for specific use cases: Ngenea for HPC – providing scratch storage, or storage for temporary user data, and Ngenea for Media & Entertainment – to accelerate post-production workflows.
Ngenea for AI is available today from Dell, from Kalray and select partners. For more information visit here.
ABOUT KALRAY
Kalray is a technology innovator specializing in software and hardware solutions to accelerate data-intensive workflows in Media & Entertainment, High-Performance Computing, and Artificial Intelligence. Our comprehensive product range features Ngenea, a leading data acceleration platform, as well as accelerated data processing cards for storage and compute.
With Kalray solutions, customers can scale their infrastructures to efficiently meet the performance and capacity needs of data-intensive tasks, all without being tied to specific data formats or vendors.
Founded in 2008 as a spin-off from the French CEA research lab, Kalray has corporate and financial backing from notable investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors, and Bpifrance. Committed to innovation and excellence, we strive to deliver value to our customers, developers, and the planet through technology and expertise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521509685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
